Docality.com Logo
 
Dr. Joshua  Portnoy  Md image

Dr. Joshua Portnoy Md

15 W Dry Creek Cir
Littleton CO 80120
303 521-1100
Medical School: Other - 1995
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: No
License #: 37670
NPI: 1952362154
Taxonomy Codes:
207RC0200X 207RP1001X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Joshua Portnoy is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99291 Description:Critical care first hour Average Price:$430.00 Average Price Allowed
By Medicare:
$210.64
HCPCS Code:99223 Description:Initial hospital care Average Price:$348.14 Average Price Allowed
By Medicare:
$192.45
HCPCS Code:36556 Description:Insert non-tunnel cv cath Average Price:$236.00 Average Price Allowed
By Medicare:
$120.21
HCPCS Code:99292 Description:Critical care addl 30 min Average Price:$217.10 Average Price Allowed
By Medicare:
$107.19
HCPCS Code:99239 Description:Hospital discharge day Average Price:$185.00 Average Price Allowed
By Medicare:
$101.76
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$181.00 Average Price Allowed
By Medicare:
$98.71
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$240.00 Average Price Allowed
By Medicare:
$158.34
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$175.00 Average Price Allowed
By Medicare:
$102.94
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$128.00 Average Price Allowed
By Medicare:
$68.87
HCPCS Code:94060 Description:Evaluation of wheezing Average Price:$112.00 Average Price Allowed
By Medicare:
$60.49
HCPCS Code:94729 Description:C02/membane diffuse capacity Average Price:$104.27 Average Price Allowed
By Medicare:
$53.04
HCPCS Code:36620 Description:Insertion catheter artery Average Price:$100.00 Average Price Allowed
By Medicare:
$50.53
HCPCS Code:94726 Description:Pulm funct tst plethysmograp Average Price:$102.65 Average Price Allowed
By Medicare:
$53.32
HCPCS Code:94010 Description:Breathing capacity test Average Price:$66.00 Average Price Allowed
By Medicare:
$35.77
HCPCS Code:94060 Description:Evaluation of wheezing Average Price:$26.00 Average Price Allowed
By Medicare:
$12.51
HCPCS Code:94726 Description:Pulm funct tst plethysmograp Average Price:$24.00 Average Price Allowed
By Medicare:
$12.17
HCPCS Code:94729 Description:C02/membane diffuse capacity Average Price:$16.00 Average Price Allowed
By Medicare:
$8.10

HCPCS Code Definitions

94729
Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)
36620
Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99239
Hospital discharge day management; more than 30 minutes
99292
Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service)
94060
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
36556
Insertion of non-tunneled centrally inserted central venous catheter; age 5 years or older
94060
Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
94726
Plethysmography for determination of lung volumes and, when performed, airway resistance
94010
Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99223
Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of high severity. Typically, 70 minutes are spent at the bedside and on the patient's hospital floor or unit.
94726
Plethysmography for determination of lung volumes and, when performed, airway resistance
94729
Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)
99291
Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1427019215
Internal Medicine
7,686
1801868401
Internal Medicine
7,342
1144294752
Diagnostic Radiology
2,620
1932162070
Infectious Disease
2,409
1780635904
Otolaryngology
1,783
1407819139
Infectious Disease
1,604
1255315578
Medical Oncology
1,600
1194711416
Infectious Disease
1,401
1134135346
Cardiovascular Disease (Cardiology)
1,394
1790857340
Critical Care (Intensivists)
1,330
*These referrals represent the top 10 that Dr. Portnoy has made to other doctors

Publications

Respiratory bronchiolitis-interstitial lung disease: long-term outcome. - Chest
The clinical and physiologic features of respiratory bronchiolitis (RB)-interstitial lung disease (ILD) have been previously described; however, the natural history and outcome have not been systematically evaluated. The majority of published reports consider RB-ILD to be a nonprogressive ILD that clinically improves with smoking cessation and antiinflammatory treatment. In this study, we sought to determine the outcome of RB-ILD patients with and without smoking cessation and with and without corticosteroid therapy.Thirty-two RB-ILD cases confirmed by surgical lung biopsy were identified from a prospectively enrolled cohort of subjects with ILD. Initial and follow-up data on symptoms, physiology, treatment, and outcome were collected and analyzed.Kaplan-Meier analysis revealed that at least 75% of RB-ILD patients survived > 7 years after diagnosis. Clinical improvement occurred in only 28% of cases, and physiologic improvement occurred in 10.5% of cases. One patient died of progressive ILD, and two patients died of non-small cell lung cancer. While physiologic improvement was limited to those who had ceased smoking, corticosteroids and/or other immunosuppressive therapy had little effect on symptoms or physiology.This study shows that prolonged survival is common in RB-ILD. However, symptomatic and physiologic improvement occurs in only a minority of patients, and neither smoking cessation nor immunosuppressive therapy is regularly associated with clinically significant benefit.
Alveolar type II cells inhibit fibroblast proliferation: role of IL-1alpha. - American journal of physiology. Lung cellular and molecular physiology
Alveolar type II (ATII) cells inhibit fibroblast proliferation in coculture by releasing or secreting a factor(s) that stimulates fibroblast production of prostaglandin E2 (PGE2). In the present study, we sought to determine the factors released from ATII cells that stimulate PGE2 production in fibroblasts. Exogenous addition of rat IL-1alpha to cultured lung fibroblasts induced PGE2 secretion in a dose-response manner. When fibroblasts were cocultured with rat ATII cells, IL-1alpha protein was detectable in ATII cells and in the coculture medium between days 8 and 12 of culture, correlating with the highest levels of PGE2. Furthermore, under coculture conditions, IL-1alpha gene expression increased in ATII cells (but not fibroblasts) compared with either cell cultured alone. In both mixed species (human fibroblasts-rat ATII cells) and same species cocultures (rat fibroblasts and ATII cells), PGE2 secretion was inhibited by the presence of IL-1 receptor antagonist (IL-1Ra) or selective neutralizing antibody directed against rat IL-1alpha (but not IL-1beta). Conditioned media from cocultures inhibited fibroblast proliferation, and this effect was abrogated by the addition of IL-1Ra. Addition of keratinocyte growth factor (KGF) resulted in an earlier increase in PGE2 secretion and fibroblast inhibition (day 8 of coculture). This effect was inhibited by indomethacin but was not altered by IL-1Ra. We conclude that in this coculture system, IL-1alpha secretion by ATII cells is one factor that stimulates PGE2 production by lung fibroblasts, thereby inhibiting fibroblast proliferation. In addition, these studies demonstrate that KGF enhances ATII cell PGE2 production through an IL-1alpha-independent pathway.
Keratinocyte growth factor stimulates alveolar type II cell proliferation through the extracellular signal-regulated kinase and phosphatidylinositol 3-OH kinase pathways. - American journal of respiratory cell and molecular biology
Keratinocyte growth factor (KGF or FGF-7) stimulates alveolar type II cell proliferation, but little is known about the signaling pathways involved. We investigated the role of the ERK (p42/44 mitogen activated protein [MAP] kinase) and phosphatidylinositol 3-OH kinase (PI3 kinase) pathways on alveolar type II cell proliferation and differentiation. Rat type II cells were cultured on tissue culture plastic and Matrigel in the presence or absence of KGF and specific chemical inhibitors PD98059, LY294002, and rapamycin at various concentrations. Proliferation was measured by thymidine incorporation and DNA quantitation, and differentiation was measured by expression of surfactant protein A and alkaline phosphatase. We demonstrate that KGF activates distal effectors of the PI3 kinase pathway, PKB/Akt, and p70S6 kinase, as well as p42/44 MAP kinase proteins. Inhibition of these pathways with PD98059, LY294002, or rapamycin inhibited type II cell proliferation but had no significant effect on differentiation. KGF did not activate the c-Jun kinase or p38 MAP kinase pathways. We conclude that the p42/44 MAP kinase and PI3 kinase pathways are important in regulating alveolar type II cell proliferation in response to KGF.

Map & Directions

15 W Dry Creek Cir Littleton, CO 80120
View Directions In Google Maps

Nearby Doctors

15 W Dry Creek Cir
Littleton, CO 80120
303 521-1100
2 W Dry Creek Cir 125
Littleton, CO 80120
303 946-6800
26 W Dry Creek Cir Ste 430
Littleton, CO 80120
303 946-6959
1001 Southpark Dr
Littleton, CO 80120
303 228-8987
20 W Dry Creek Cir Ste 300
Littleton, CO 80120
303 692-2900
5984 S Prince St Ste 101
Littleton, CO 80120
303 381-1021
2 W Dry Creek Cir Ste 125
Littleton, CO 80120
303 946-6800
26 W Dry Creek Cir Suite 720
Littleton, CO 80120
303 945-5138
8199 Southpark Ln Suite 100
Littleton, CO 80120
303 303-3332
1501 W Campus Dr Unit I
Littleton, CO 80120
303 950-0389